Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

833 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
Kim MK, Cho KJ, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Song HJ, Ryu JS, Kim SB. Kim MK, et al. Among authors: ryu js. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):115-21. doi: 10.1016/j.ijrobp.2008.10.074. Epub 2009 Feb 27. Int J Radiat Oncol Biol Phys. 2009. PMID: 19251379
Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer.
Choi NC, Fischman AJ, Niemierko A, Ryu JS, Lynch T, Wain J, Wright C, Fidias P, Mathisen D. Choi NC, et al. Among authors: ryu js. Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1024-35. doi: 10.1016/s0360-3016(02)03038-9. Int J Radiat Oncol Biol Phys. 2002. PMID: 12419428
Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
Kim MK, Ryu JS, Kim SB, Ahn JH, Kim SY, Park SI, Kim YH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH. Kim MK, et al. Among authors: ryu js. Eur J Cancer. 2007 Jun;43(9):1385-91. doi: 10.1016/j.ejca.2007.04.001. Epub 2007 May 23. Eur J Cancer. 2007. PMID: 17512192 Clinical Trial.
Treatment outcome and recursive partitioning analysis-based prognostic factors in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy.
Kim MK, Kim SB, Ahn JH, Kim YH, Kim JH, Jung HY, Lee GH, Choi KD, Song HY, Shin JH, Cho KJ, Ryu JS, Park SI. Kim MK, et al. Among authors: ryu js. Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):725-34. doi: 10.1016/j.ijrobp.2007.10.009. Epub 2007 Dec 31. Int J Radiat Oncol Biol Phys. 2008. PMID: 18164836 Clinical Trial.
Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Kang BW, Kim WS, Kim C, Jang G, Lee SS, Choi YH, Lee DH, Kim SW, Kim S, Ryu JS, Huh J, Lee JS, Suh C. Kang BW, et al. Among authors: ryu js. Invest New Drugs. 2010 Aug;28(4):516-22. doi: 10.1007/s10637-009-9283-z. Epub 2009 Jun 23. Invest New Drugs. 2010. PMID: 19547918 Clinical Trial.
833 results